Damora Therapeutics, Inc.
Key Metrics
- Previous Close
- $30.82
- 52-Week Range
- $2.45 – $38.33
- Market Cap
- $1.87B
- P/E (TTM)
- —
- EPS (TTM)
- -0.25
- Dividend Yield
- —
Advanced Metrics
- Price/Book
- 4.85
- PEG Ratio
- —
- Return on Equity
- -99.74%
- Return on Assets
- -21.61%
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Profit Margin
- 0.00%
- Current Ratio
- 19.73
- Debt/Equity
- —
- Total Debt
- $0.00
- Free Cash Flow
- $-15.98M
- Revenue Growth
- —
- Earnings Growth
- —
- Enterprise Value
- $1.46B
Market Snapshot
About
Damora Therapeutics Inc (DMRA) is a biotechnology company based in Waltham, Massachusetts, focused on developing new treatments for serious blood disorders and related cancers. Founded in 2011, the company's research primarily targets hematologic diseases, with operations noted in Denmark and North America.
The company’s central pipeline involves therapies aimed at mutations in a gene called CALR. Its lead investigational product is DMR-001, a monoclonal antibody designed for the treatment of essential thrombocythemia, a type of myeloproliferative neoplasm. Damora also has follow-up candidates, DMR-002 and DMR-003, which are described as anti-mutCALR-based therapies intended to address a broader range of patients with these CALR-mutant disorders.
In addition to its CALR-targeted programs, Damora Therapeutics is developing a small molecule inhibitor named GB3226. This compound aims to block two pathways, ENL-YEATS and FLT3, and is being researched for the treatment of acute myeloid leukemia. The company’s strategy is built on advancing these investigational therapies through development to address unmet medical needs in hematology and oncology.